OP-1206, a prostaglandin E1 derivative. Effects of oral administration to patients with chronic lung disease.
In order to assess the clinical effectiveness of an oral prostaglandin E1 derivative, OP-1206, five patients with chronic obstructive pulmonary disease and two with pulmonary fibrosis were studied from the standpoint of hemodynamics and nine others with chronic lung disease from the standpoint of respiratory function. Oral intake of OP-1206 resulted in a significant decrease in the pulmonary arterial pressure (p less than 0.01), total pulmonary vascular resistance (p less than 0.01), pulmonary arteriole resistance (p less than 0.01), and total systemic vascular resistance (p less than 0.05), and an increase in the cardiac index (p less than 0.05) and oxygen delivery (p less than 0.01) with insignificant changes of PaCO2, PaO2 and pH. There was no clinical improvement of lung function after OP-1206 intake. OP-1206 is a potent vasodilator, improving cardiac performance in patients with chronic lung disease and possibly preventing the progress of cor pulmonale in this kind of patient.
D000368:Aged; D000527:Alprostadil / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D011658:Pulmonary Fibrosis / Q000188:drug therapy; D011660:Pulmonary Heart Disease / Q000517:prevention & control; D012129:Respiratory Function Tests; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
D011459:Prostaglandins E, Synthetic; D014665:Vasodilator Agents; C025090:ONO 1206; D000527:Alprostadil